Congress Presses Mylan, FDA to Explain EpiPen Price

August 31, 2016

Despite Mylan’s efforts to quell criticism, U.S. lawmakers continue to press the company and the FDA for greater transparency on the cost of the company’s EpiPen epinephrine auto-injector.

In less than a decade, the price of an EpiPen two-pack has risen to $608, up from about $100 in 2008, without a clear explanation, prompting Reps. Jason Chaffetz (R-Utah) and Elijah E. Cummings (D-Md.) to request documents on product revenues and expenses Monday.

In a letter to Mylan CEO Heather Bresch, the chairman of the House Oversight and Government Reform committee and its ranking Democrat asked the company to disclose its EpiPen profits dating back to when the company first acquired the product in 2007.

Reps. Fred Upton (R-Mich.), Joseph Pitts (R-Pa.) and Tim Murphy (R-Pa.) penned a separate letter to the FDA centered on the lack of generic competition the EpiPen faces on the market.

View today's stories